Menu

Dermatology Clinical Trials - Alan R. Shalita Clinical Research Unit

We are recruiting patients for our active clinical trials. If you are interested in participating or obtaining more information, please contact our Dermatology Research Department at (718) 270-1229.

Currently Enrolling

PSORIASIS

ENROLLING NOW! Apremilast (Otezla) (SUNY – Dr. Jakus)

  • Children ages 6-17 years old
  • Mild or Moderate Plaque Psoriasis

Phone: (347) 286-8825, Email: tristi.edwards@downstate.edu 

ENROLLING NOW! Cardiovascular Disease Prevention for Psoriasis and Psoriatic Artritis (CP3) (SUNY – Dr. Jakus)

  • Age 40-75
  • Being seen by a dermatology  provider for the primary encounter of psoriasis

Phone: (347) 286-8825, Email: tristi.edwards@downstate.edu

ATOPIC DERMATITIS

ENROLLING NOW! Soquelitinib (SUNY – Dr. Jakus)

  • Ages 18+
  • Moderate to severe atopic dermatitis

Phone: (347) 286-8825, Email: tristi.edwards@downstate.edu

VITILIGO  

ENROLLING NOW! Ruxolitinib in Pediatric Non-Segmental Vitiligo                (SUNY – Dr. Jakus)

  • Ages 2 to <12 years

Phone: (347) 286-8825, Email: tristi.edwards@downstate.edu

HIDRADENITIS SUPPURATIVA 

RECRUITING SOON! Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (SUNY- Dr. Jakus)

  • Ages 12+
  • Mild to moderate HS

Phone: (347) 286-8825, Email: tristi.edwards@downstate.edu

ATOPIC DERMATITIS

RECRUITING SOON! Investigational compound(s) in patients with atopic dermatitis

  • Ages 18+
  • Moderate to severe Atopic Dermatitis

Phone: (347) 286-8825, Email: tristi.edwards@downstate.edu

OTHER

Psoriasis (SUNY- Dr. Lee)

NEW: After completion of the phase IIb psoriasis trial, a first-in-class botanical topical cream will be tested in a placebo-controlled phase Iii study for adults ages 18-70 (SUNY-Dr. Heilman) and for peds ages 2-12 (SUNY-Dr. Glick). Sponsored by Psoriasis Institute of Guangzhou (PRIG), China. ClinicalTrials.gov/NCT03372811  

Ongoing recruitment: 50 adult subjects with mild to moderate psoriasis (BSA between 1 to 20). The total participation time will be 12 weeks: 8 weeks of treatment period with 4 additional weeks for extended assessment/evaluation. 

Upcoming recruitment for 10 ped patients (date to start: to be announced)

Please contact Neal Gupta, MD or Wei-Li Lee, PhD at the department of dermatology at (718) 270-1229


Anticipating Enrollment Soon

PSORIASIS

Oral Phosphodiesterase Inhibitor In Mild-Moderate Pediatric Psoriasis (SUNY – Dr. Jakus)

Oral PDE4 inhibitor for pediatric patients with mild-moderate psoriasis; ages 6-17 yo, 32 weeks of active treatment

HIDRADENITIS SUPPURATIVA

HS and Laser Hair Removal

Adjunct treatment for hidradenitis suppurativa with hair removal laser


Contact Information

For Patients:

We make our best effort to keep this page current, however the study list may not be comprehensive as our studies change all the time. For more information, please feel free to reach out to us. We are happy to answer any questions you may have. When emailing, please indicate the study title in the subject line: (ie. "PSORIASIS", "ACNE"). See below for our contact information.

For Physicians:

Information on all interested patients should be forwarded to our fellows as soon as possible. Patients should also be given the information below to contact our offices directly.

 

Jeannette Jakus, MD, MBA
Director of Clinical Trials & Research
Jeannette.Jakus@downstate.edu

Corinna Psomadakis, MD
(Dr. Jakus's studies) Dermatology Research Fellow - Clinical Trials Corinna.Psomadakis@downstate.edu

Beatrice Wojuola
Clinical Research Coordinator
Beatrice.Wojuola@downstate.edu

Phone: (718) 270-1229

Email: DermResearch@downstate.edu